Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

Journal of Virology

Volumn 74, Issue 6, 2000, Pages 2740-2751

  Ourmanov, Ilnour ^a   Brown, Charles R ^a   Moss, Bernard ^a   Carroll, Miles ^a   Wyatt, Linda ^a   Pletneva, Liuobov ^a   Goldstein, Simoy ^a   Venzon, David ^b   Hirsch, Vanessa M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; IMMUNIZATION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIREMIA; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; FUSION PROTEINS, GAG-POL; GENE EXPRESSION; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV ENVELOPE PROTEIN GP120; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; RECOMBINATION, GENETIC; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 0034093217     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.6.2740-2751.2000     Document Type: Article

References (75)

1. Abimuki, A. G., M. Robert-Guroff, J. Benson, J. Tartaglia, E. Paoletti, R. C. Gallo, P. D. Markham, and G. Franchini. 1997. Long-term survival of SIVmac251-infected macaques previously immunized with NYVAC-SIV vaccines. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:S78-S85.
2. Almond, N., K. Kent, M. Cranage, E. Rud, B. Clarke, and E. J. Stott. 1995. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342-1344.
3. Almond, N. M., and J. L. Heeney. 1998. AIDS vaccine development in primate models. AIDS 12(Suppl. A):S133-S140.
4. Altenburger, W., C. P. Suter, and J. Altenburger. 1989. Partial deletion of the human host range gene in attenuated vaccinia virus MVA. Arch. Virol. 105:15-27.
5. Andersson, S., B. Makitalo, R. Thorstensson, G. Franchini, J. Tartaglia, K. Limbach, E. Paoletti, P. Putkonen, and G. Biberfeld. 1996. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J. Infect. Dis. 174:977-985.
6. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
7. Baba, T. W., Y. S. Jeong, D. Pennick, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenecity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825.
8. Baum, L. L., K. J. Cassutt, K. Knigge, R. Khattri, J. Margolick, C. Rinaldo, C. A. Kleeberger, P. Nishanian, D. R. Henrard, and J. Phair. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:2168-2173.
9. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:8264-8272.
10. Benson, J., C. Chougnet, M. Robert-Guroff, D. Montefiori, P. Markham, G. Shearer, R. C. Gallo, M. Cranage, E. Paoletti, K. Limbach, D. Venzon, J. Tartaglia, and G. Franchini. 1998. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251: dependence on route of challenge exposure. J. Virol. 72:4170-4182.
11. Benveniste, R. E., W. R. Morton, E. A. Clarck, C. C. Tsai, H. D. Ochs, J. M. Ward, L. Kuller, W. B. Knott, R. W. Hill, M. J. Gale, and M. E. Thouless. 1988. Inoculations of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2. J. Virol. 62:2091-2101.
12. Berglund, P., M. Quesada-Rolander, P. Putkonen, G. Biberfeld, R. Thorstensson, and P. Liljestrom. 1997. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retrovir. 13:1487-1495.
13. Blanchard, T. J., A. Alcami, A. Panayota, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lack several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1159-1167.
14. Buge, S. L., E. Richardson, S. Alipanah, P. Markham, S. Cheng, N. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff. 1997. An adenovirus simian immunodeficiency virus Env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:8531-8541.
15. Caley, I. J., M. R. Betts, D. M. Irlbeck, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type I immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:3031-3038.
16. Carroll, M., and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propargation and generation of recombinant viruses in nonhuman mammalian cell line. Virology 244: 365-396.
17. Chackrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 21: 1904-1907.
18. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992, Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
19. Denisova, G., B. Stern, D. Raviv, J. Zwickel, N. I. Smorodinsky, and J. M. Gershoni. 1996. Humoral immune response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res. Hum. Retrovir. 12:901-909.
20. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. M. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431-1437.
21. Earl, P. L., N. Cooper, L. S. Wyatt, M. W. Carroll, O. Elroy-Stein, and B. Moss. 1998. Expression of proteins in mammalian cells using vaccinia viral vectors, p. 16.15.1-16.19.11. In F. M. Ausubel et al. (ed.), Current protocols in molecular biology. John Wiley and Sons, Inc., New York, N.Y.
22. Excler, J. L., and S. Plotkin. 1997. The prime-boost concept applied to HIV preventive vaccines. AIDS 11(Suppl. A):S127-S137.
23. Glamann, J., D. R. Burton, P. W. H. I. Parren, H. J. Ditzel, K. A. Kent, C. Arnold, D. Montefiori, and V. M. Hirsch. 1998. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. J. Virol. 72:585-592.
24. Goh, W. C., J. Markee, R. E. Akridge, M. Meldorf, L. Musey, T. Karchmer, M. Krone, A. Collier, L. Corey, M. Emerman, and M. J. McElrath. 1999. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J. Infect. Dis. 179:548-557.
25. Goldstein, S., W. R. Elkins, W. T. London, A. Hahn, R. Goeken, J. E. Martin, and V. M. Hirsch. 1994. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J. Med. Primatol. 23:75-82.
26. Haigwood, N. L., L. E. Misher, S. M. Chin, M. Blair, V. Planelles, C. J. Scandella, K. S. Steimer, M. B. Gardner, T. Yilma, V. M. Hirsch, and P. R. Johnson. 1992. Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. J. Med. Primatol. 21:82-90.
27. Haigwood, N. L., A. Watson, W. F. Sutton, J. McCure, A. Lewis, J. Ranchis, B. Travis, G. Voss, N. Letvin, S.-L. Hu, V. M. Hirsch, and P. R. Johnson. 1996. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:107-114.
28. Haigwood, N. L., and S. Zolla-Pazner. 1998. Humoral immunity to HIV, SIV, and SHIV. AIDS 12(Suppl. A):S121-S132.
29. Hanke, T., T. J. Blanchard, J. Schneider, G. S. Ogg, R. Tan, M. Becker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. McMichael. 1998. Immunogenicity of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 79:83-90.
30. Hanke, T., V. C. Neumann, T. J. Blanchard, P. Sweeney, A. V. S. Hill, G. L. Smith, and A. McMichael. 1999. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17: 589-596.
31. Hanke, T., R. V. Samuel, T. J. Blanchard, V. C. Neumann, T. M. Allen, J. E. Boyson, S. A. Sharpe, N. Cook, G. L. Smith, D. I. Watkins, M. P. Cranage, and A. J. McMichael. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
32. Hirsch, V. M., and P. R. Johnson. 1994. Pathogenic diversity of simian immunodeficiency viruses. Virus Res. 32:183-203.
33. Hirsch, V. M., G. Dapolito, P. R. Johnson, W. R. Elkins, W. T. London, R. J. Montali, S. Goldstein, and C. Brown. 1995. Induction of AIDS by simian immunodeficiency virus from and African green monkey: species-specific variation in pathogenicity correlates with extent of in vivo replication. J. Virol. 69:955-967.
34. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
35. Hirsch, V. M., D. Adger-Johnson, B. Campbell, S. Goldstein, C. Brown, W. R. Elkins, and D. Montefiori. 1997. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J. Virol. 71:1608-1620.
36. Johnson, P. R., D. C. Montefiori, S. Goldstein, T. E. Hamm, J. Zhou, S. Kitov, N. L. Haigwood, L. Misher, W. T. London, J. L. Gerin, A. Allison, R. H. Purcell, R. M. Chanock, and V. M. Hirsch. 1992. Inactivated whole-virus vaccine derived from a proviral molecular clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc. Natl. Acad. Sci. USA 89: 2175-2179.
37. Johnson, R. P., and R. C. Desrosiers. 1998. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Biol. 10:436-443.
38. Johnson, R. P., J. D. Lifson, S. C. Czajak, K. S. Cole, K. H. Manson, R. Glickman, J. Yang, D. C. Montefiori, R. Montelaro, M. S. Wyand, and R. C. Desrosiers. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73:4952-4961.
39. Kaplan, E. L. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-466.
40. Koup, R. A., J. T. Safrit, Y. Z. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type-1 syndrome. J. Virol. 68:4650-4655.
41. Kuroda, M. J., J. E. Schmitz, W. A. Charini, C. E. Nickerson, M. A. Lifton, C. I. Lord, M. A. Forman, and N. L. Lettin. 1999. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162:5127-5133.
42. Leno, M., L. Carter, D. J. Venzon, J. Romano, P. D. Markham, K. Limbach, J. Tartaglia, E. Paoletti, J. Benson, G. Franchini, and M. Robert-Guroff. 1999. CD8(+) lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy. AIDS Res. Hum. Retrovir. 15:461-470.
43. Letvin, N. L. 1998. Progress in the development of an HIV-1 vaccine. Science 280:1875-1880.
44. Levy, J. A. 1996. The value of primate models for studying human immunodeficiency virus pathogenesis. J. Med. Primatol. 25:163-174.
45. Mahmood, N., and A. J. Hay. 1992. An ELISA utilizing immobilized snowdrop lectin GNA for the detection of envelope glycoproteins of HIV and SIV. J. Immunol. Methods 151:9-13.
46. Mahnel, H., and A. Mayr. 1994. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berl. Muench. Tieraerztl. Wochenschr. 107:253-256.
47. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. 1975. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammmes MVA. Infection 3:6-14.
48. Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism. Zentralbl. Bakteriol. Hyg. B 167:375-390.
49. Meyer, H., G. Sutter, and A. Mayr. 1992. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
50. Montefiori, D. C., and T. G. Evans. 1999. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res. Hum. Retrovir. 15:689-698.
51. Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. M. Hirsch, S. Goldstein, W. R. Elkins, J. D. Lifson, M. Piatak, N. P. Restifo, W. Owerwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397:7-13.
52. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O'Neil, D. Riley, D. H. Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70:1953-1960.
53. Nathanson, N., V. M. Hirsch, and B. J. Mathieson. 1999. The role of nonhuman primate models in the development of an AIDS vaccine. AIDS 13 (Suppl. A):S113-S120.
54. Norley, S., B. Beer, D. Binninger-Schinzel, C. Cosma, and R. Kurth. 1996. Protection from pathogenic SIVmac challenge following short-term infection with a Nef-deficient attenuated virus. Virology 219:195-205.
55. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Z. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMickael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
56. Ourmanov, I., M. Bilska, V. M. Hirsch, and D. C. Montefiori. 2000 Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J. Virol. 74:2960-2965.
57. Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
58. Perkus, M. E., J. Tartaglia, and E. Paoletti. 1995. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J. Leukocyte Biol. 58:1-13.
59. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K.-C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
60. Piatak, M., K.-C. Luk, B. Williams, and J. D. Lifson. 1993. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. BioTechniques 14:70-77.
61. Planelles, V., N. L. Haigwood, M. L. Mathas, K. A. Mann, C. J. Scandella, W. D. Lidster, J. R. Schuster, R. van Kuyk, P. A. Marx, M. B. Gardner, and P. A. Luciw. 1991. Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res. Hum. Retrovir. 7:889-896.
62. Polacino, P., V. Stallard, D. C. Montefiori, C. R. Brown, B. A. Richardson, W. R. Morton, R. E. Benveniste, and S. L. Hu. 1999. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J. Virol. 73:3134-3146.
63. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
64. Robert-Guroff, M., H. Kaur, L. J. Patterson, M. Leno, A. J. Conley, P. M. McKenna, P. D. Markham, E. Richardson, K. Aldrich, K. Arora, L. Murty, L. Carter, S. Zolla-Pazner, and F. Sinangil. 1998. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J. Virol. 72:10275-10280.
65. Rud, E. W., M. Cranage, and J. Yon. 1994. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J. Gen. Virol. 75:529-543.
66. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes. Science 283:857-860.
67. Schulz, A. 1998. Using recombinant vectors as HIV vaccine. IAVI Report 3: 1-4.
68. Seth, A., I. Ourmanov, M. J. Kuroda, J. E. Schmitz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin. 1998. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by major histocompatibility complex class I/peptide tetramer. Proc. Natl. Acad. Sci. USA 95:10112-10116.
69. Seth, A., I. Ourmanov, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, L. Wyatt, M. Carroll, B. Moss, D. Venzon, N. L. Letvin, and V. M. Hirsch. 2000. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74:2502-2509.
70. Suryanarayana, K., T. A. Wiltrout, G. M. Vasques, V. M. Hirsch, and J. D. Lifson. 1998. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chane reaction. AIDS Res. Hum. Retrovir. 14:183-189.
71. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
72. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A recombinant vector derived from the host-range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040.
73. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.
74. Wyand, M. S., K. H. Manson, A. A. Lackner, and R. C. Desrosiers. 1997. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat. Med. 3:32-36.
75. Zhang, J.-Y., L. N. Martin, E. A. Watson, R. C. Monteralo, M. West, L. Epstein, and M. Murphey-Corb. 1998. Simian immunodeficiency virus/Delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia. J. Infect. Dis. 158:1277-1286.